FDA 483 - Mohnark Pharmaceuticals Inc - February 25, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Mohnark Pharmaceuticals Inc, an OTC drug manufacturer in Davie, FL, revealed significant deficiencies across multiple areas. The firm was cited for lacking adequate quality control procedures, failing to properly test raw materials, and maintaining incomplete production records. Additionally, issues were noted regarding inadequate dust control equipment and unsuitable building construction, indicating a lack of current Good Manufacturing Practices.
ID · 721b5be7-e90a-4eca-9126-b822600444d3